Myriad Genetics, Inc. (NASDAQ:MYGN) – William Blair issued their Q1 2019 earnings per share (EPS) estimates for Myriad Genetics in a research report issued on Thursday. William Blair analyst A. Murphy anticipates that the company will post earnings of $0.22 per share for the quarter. William Blair also issued estimates for Myriad Genetics’ Q2 2019 earnings at $0.23 EPS, Q3 2019 earnings at $0.29 EPS and Q4 2019 earnings at $0.35 EPS.

MYGN has been the topic of a number of other research reports. Jefferies Group LLC reiterated a “hold” rating and issued a $23.00 target price (up previously from $21.00) on shares of Myriad Genetics in a report on Thursday, August 10th. Cowen and Company reiterated a “hold” rating and issued a $25.00 target price on shares of Myriad Genetics in a report on Sunday, September 17th. BidaskClub upgraded Myriad Genetics from a “sell” rating to a “hold” rating in a report on Friday, June 9th. Deutsche Bank AG upgraded Myriad Genetics from a “sell” rating to a “hold” rating and dropped their target price for the company from $27.86 to $15.00 in a report on Friday, August 18th. Finally, Stephens reiterated an “overweight” rating and issued a $40.00 target price (up previously from $36.00) on shares of Myriad Genetics in a report on Friday, September 22nd. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $24.18.

TRADEMARK VIOLATION NOTICE: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/10/06/analysts-offer-predictions-for-myriad-genetics-inc-s-q1-2019-earnings-mygn.html.

Myriad Genetics (NASDAQ:MYGN) traded up 0.63% during midday trading on Friday, reaching $36.74. 359,777 shares of the company were exchanged. The stock has a market capitalization of $2.51 billion, a price-to-earnings ratio of 115.17 and a beta of 0.28. The firm’s 50-day moving average price is $32.41 and its 200 day moving average price is $24.80. Myriad Genetics has a 52-week low of $15.15 and a 52-week high of $37.14.

Myriad Genetics (NASDAQ:MYGN) last released its earnings results on Tuesday, August 8th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.04. Myriad Genetics had a net margin of 2.83% and a return on equity of 9.67%. The firm had revenue of $200.50 million during the quarter, compared to the consensus estimate of $193.71 million. During the same period in the previous year, the firm earned $0.36 earnings per share. Myriad Genetics’s revenue was up 7.5% compared to the same quarter last year.

In other Myriad Genetics news, Director John T. Henderson sold 30,000 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $30.30, for a total transaction of $909,000.00. Following the completion of the sale, the director now owns 52,524 shares of the company’s stock, valued at $1,591,477.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.20% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the business. Arizona State Retirement System bought a new stake in Myriad Genetics during the first quarter worth approximately $682,000. Airain ltd bought a new stake in Myriad Genetics during the second quarter worth approximately $1,097,000. PDT Partners LLC bought a new stake in Myriad Genetics during the second quarter worth approximately $8,481,000. Bank of New York Mellon Corp boosted its position in shares of Myriad Genetics by 131.2% in the first quarter. Bank of New York Mellon Corp now owns 918,305 shares of the company’s stock valued at $17,632,000 after acquiring an additional 521,146 shares during the period. Finally, Blair William & Co. IL bought a new stake in shares of Myriad Genetics in the second quarter valued at approximately $1,048,000.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Earnings History and Estimates for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.